Anika Therapeutics (ANIK) Q4 2024 Annual Earnings
ANIK·Reported March 12, 2025·After market close
Anika Therapeutics reported Q4 2024 revenue of -$1.3M, missed analyst consensus of $28.1M by $29.4M. Diluted EPS came in at $-0.03, missed the $-0.01 consensus by $0.02.
Revenue
-$1.3Mmissed by $29.4M
Consensus: $28.1MDiluted EPS
$-0.03missed by $0.02
Consensus: $-0.01
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Anika Therapeutics's Q4 2024 earnings report.
Anika Therapeutics (ANIK) reported Q4 2024 earnings on March 12, 2025 after market close.
Anika Therapeutics reported revenue of -$1.3M and diluted EPS of $-0.03 for Q4 2024.
Revenue missed the consensus estimate of $28.1M by $29.4M. EPS missed the consensus estimate of $-0.01 by $0.02.
You can read the 10-K periodic report (0001171843-25-001486) directly on SEC EDGAR. The filing index links above go to sec.gov.